X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE PANACEA BIOTECH SUVEN LIFE/
PANACEA BIOTECH
 
P/E (TTM) x 19.3 169.7 11.4% View Chart
P/BV x 3.6 3.8 95.0% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 SUVEN LIFE   PANACEA BIOTECH
EQUITY SHARE DATA
    SUVEN LIFE
Mar-16
PANACEA BIOTECH
Mar-14
SUVEN LIFE/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs339149 227.6%   
Low Rs14482 175.5%   
Sales per share (Unadj.) Rs39.284.1 46.6%  
Earnings per share (Unadj.) Rs7.5-18.3 -40.8%  
Cash flow per share (Unadj.) Rs8.8-6.7 -131.0%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs49.083.7 58.5%  
Shares outstanding (eoy) m127.2861.25 207.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.21.4 448.2%   
Avg P/E ratio x32.4-6.3 -512.9%  
P/CF ratio (eoy) x27.5-17.2 -159.6%  
Price / Book Value ratio x4.91.4 357.1%  
Dividend payout %26.80-   
Avg Mkt Cap Rs m30,7327,074 434.4%   
No. of employees `0001.02.8 34.7%   
Total wages/salary Rs m4161,449 28.7%   
Avg. sales/employee Rs Th5,236.11,874.1 279.4%   
Avg. wages/employee Rs Th436.5527.0 82.8%   
Avg. net profit/employee Rs Th995.5-407.7 -244.1%   
INCOME DATA
Net Sales Rs m4,9955,154 96.9%  
Other income Rs m194100 193.9%   
Total revenues Rs m5,1895,254 98.8%   
Gross profit Rs m1,233-766 -160.9%  
Depreciation Rs m167711 23.5%   
Interest Rs m541,503 3.6%   
Profit before tax Rs m1,205-2,881 -41.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m25517 1,517.9%   
Profit after tax Rs m950-1,121 -84.7%  
Gross profit margin %24.7-14.9 -166.0%  
Effective tax rate %21.2-0.6 -3,629.3%   
Net profit margin %19.0-21.8 -87.4%  
BALANCE SHEET DATA
Current assets Rs m4,9863,810 130.9%   
Current liabilities Rs m1,0428,365 12.5%   
Net working cap to sales %79.0-88.4 -89.3%  
Current ratio x4.80.5 1,050.3%  
Inventory Days Days61156 39.2%  
Debtors Days Days3967 58.2%  
Net fixed assets Rs m3,12614,480 21.6%   
Share capital Rs m12761 207.7%   
"Free" reserves Rs m3,717903 411.6%   
Net worth Rs m6,2365,127 121.6%   
Long term debt Rs m4325,832 7.4%   
Total assets Rs m8,07919,433 41.6%  
Interest coverage x23.2-0.9 -2,534.3%   
Debt to equity ratio x0.11.1 6.1%  
Sales to assets ratio x0.60.3 233.1%   
Return on assets %12.42.0 632.6%  
Return on equity %15.2-21.9 -69.6%  
Return on capital %18.93.6 519.1%  
Exports to sales %87.524.5 356.8%   
Imports to sales %12.210.2 120.1%   
Exports (fob) Rs m4,3711,264 345.8%   
Imports (cif) Rs m611525 116.4%   
Fx inflow Rs m4,6661,539 303.2%   
Fx outflow Rs m942942 100.0%   
Net fx Rs m3,724597 623.6%   
CASH FLOW
From Operations Rs m922599 153.9%  
From Investments Rs m-619-438 141.4%  
From Financial Activity Rs m-698-303 230.8%  
Net Cashflow Rs m-396-141 280.0%  

Share Holding

Indian Promoters % 63.4 74.5 85.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.6 -  
FIIs % 0.0 1.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 23.6 154.7%  
Shareholders   37,287 10,259 363.5%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SHASUN PHARMA  

Compare SUVEN LIFE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Feb 20, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUVEN LIFE 8-QTR ANALYSIS

COMPARE SUVEN LIFE WITH

MARKET STATS